Your browser doesn't support javascript.
loading
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies.
Sheng, Qing; D'Alessio, Joseph A; Menezes, Daniel L; Karim, Christopher; Tang, Yan; Tam, Angela; Clark, Suzanna; Ying, Chi; Connor, Anu; Mansfield, Keith G; Rondeau, Jean-Michel; Ghoddusi, Majid; Geyer, Felipe C; Gu, Jane; McLaughlin, Margaret E; Newcombe, Rick; Elliot, GiNell; Tschantz, William R; Lehmann, Sylvie; Fanton, Christie P; Miller, Kathy; Huber, Thomas; Rendahl, Katherine G; Jeffry, Ursula; Pryer, Nancy K; Lees, Emma; Kwon, Paul; Abraham, Judith A; Damiano, Jason S; Abrams, Tinya J.
  • Sheng Q; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • D'Alessio JA; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Menezes DL; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Karim C; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Tang Y; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Tam A; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Clark S; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Ying C; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Connor A; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Mansfield KG; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Rondeau JM; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Ghoddusi M; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Geyer FC; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Gu J; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • McLaughlin ME; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Newcombe R; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Elliot G; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Tschantz WR; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Lehmann S; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Fanton CP; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Miller K; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Huber T; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Rendahl KG; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Jeffry U; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Pryer NK; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Lees E; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Kwon P; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Abraham JA; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Damiano JS; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Abrams TJ; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts. tinya.abrams@novartis.com.
Mol Cancer Ther ; 20(7): 1270-1282, 2021 07.
Article en En | MEDLINE | ID: mdl-33879555
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Cadherinas / Inmunoconjugados / Antineoplásicos Inmunológicos / Neoplasias Límite: Animals / Humans Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Cadherinas / Inmunoconjugados / Antineoplásicos Inmunológicos / Neoplasias Límite: Animals / Humans Idioma: En Año: 2021 Tipo del documento: Article